Cognition Therapeutics Overview

  • Founded
  • 2007

Founded
  • Status
  • Public

  • Employees
  • 21

Employees
  • Stock Symbol
  • CGTX

Stock Symbol
  • Share Price
  • $1.84

  • (As of Friday Closing)

Cognition Therapeutics General Information

Description

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Contact Information

Website
www.cogrx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 2500 Westchester Avenue
  • Purchase
  • New York, NY 10577
  • United States
+1 (412) 000-0000

Cognition Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cognition Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.84 $1.64 $1.50 - $13.80 $37.1M 22.6M 55K -$0.87

Cognition Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 7,370 215,721
Revenue 0 0 0 0
EBITDA (15,161) (10,730) (5,990) (3,737)
Net Income (15,777) (11,716) (7,839) (4,842)
Total Assets 58,696 59,137 7,119 7,459
Total Debt 1,395 0 12,852 6,901
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cognition Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cognition Therapeutics‘s full profile, request access.

Request a free trial

Cognition Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Cognition Therapeutics‘s full profile, request access.

Request a free trial

Cognition Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of inn
Drug Discovery
New York, NY
21 As of 2021
000.00
0000 0000-00-00
00000000 000.00

000 00

ion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
0000 000000000
Boston, MA
0 As of 0000
000.00
0000000000 0 000.00

000000

abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000 000000000
Clarksville, MD
0 As of 0000
00.000
00000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cognition Therapeutics Competitors (47)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
EIP Pharma Venture Capital-Backed Boston, MA 0 000.00 0000000000 0 000.00
000000000000 Venture Capital-Backed Clarksville, MD 0 00.000 00000000000
0000000 Venture Capital-Backed Framingham, MA 00 000.00 00000000000 000.00
0000000 0000000000 Venture Capital-Backed Newton, MA 0 000.00 00000000000 000.00
0000 000000 Formerly VC-backed San Diego, CA 00 00000 00000000 00000
You’re viewing 5 of 47 competitors. Get the full list »

Cognition Therapeutics Patents

Cognition Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200338045-A1 Isoindoline compositions and methods for treating neurodegenerative disease Pending 01-Nov-2017 00000000000
EP-3704092-A1 Isoindoline compositions and methods for treating neurodegenerative disease Pending 01-Nov-2017 00000000000
EP-3704092-A4 Isoindoline compositions and methods for treating neurodegenerative disease Pending 01-Nov-2017 00000000000
AU-2018269964-A1 Compositions for treating neurodegenerative diseases Pending 15-May-2017 00000000000
EP-3634394-A1 Compositions for treating neurodegenerative diseases Pending 15-May-2017 C07D295/192
To view Cognition Therapeutics’s complete patent history, request access »

Cognition Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Lisa Ricciardi Chief Executive Officer & Board Member
James O'Brien Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Anthony Caggiano MD Chief Medical Officer & Executive
Michael Grundman MD Senior Medical advisor
Aline Sherwood Associate
You’re viewing 5 of 11 executive team members. Get the full list »

Cognition Therapeutics Board Members (14)

Name Representing Role Since
Aaron Fletcher Ph.D Bios Partners Board Member 000 0000
Brett Monia Ph.D Self Board Member 000 0000
Jack Khattar Self Chairman & Board Member 000 0000
Lisa Ricciardi Cognition Therapeutics Chief Executive Officer & Board Member 000 0000
Peggy Wallace Golden Seeds Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Cognition Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cognition Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cognition Therapeutics‘s full profile, request access.

Request a free trial